429 related articles for article (PubMed ID: 30150078)
1. Cannabidiol for Epilepsy: New Hope on the Horizon?
Sanmartin PE; Detyniecki K
Clin Ther; 2018 Sep; 40(9):1438-1441. PubMed ID: 30150078
[TBL] [Abstract][Full Text] [Related]
2. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Golub V; Reddy DS
Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
[TBL] [Abstract][Full Text] [Related]
5. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
[TBL] [Abstract][Full Text] [Related]
12. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects.
Sekar K; Pack A
F1000Res; 2019; 8():. PubMed ID: 30854190
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol as potential treatment in refractory pediatric epilepsy.
Paolino MC; Ferretti A; Papetti L; Villa MP; Parisi P
Expert Rev Neurother; 2016; 16(1):17-21. PubMed ID: 26567560
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of cannabinoids.
Anciones C; Gil-Nagel A
Epileptic Disord; 2020 Jan; 22(S1):29-32. PubMed ID: 31941644
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
18. A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
Cross JH; Cock H
Neuropharmacology; 2020 Jun; 170():107861. PubMed ID: 31770546
[TBL] [Abstract][Full Text] [Related]
19. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
[TBL] [Abstract][Full Text] [Related]
20. The case for assessing cannabidiol in epilepsy.
Cilio MR; Thiele EA; Devinsky O
Epilepsia; 2014 Jun; 55(6):787-90. PubMed ID: 24854434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]